Furthermore, a systematic review of 207 published cases of TNF-α inhibitor-induced psoriasiform eruptions demonstrated that the risk of such adverse events is not affected by the underlying disease treated with the TNF-α inhibitor, which included psoriasis, psoriatic arthritis, RA, inflammatory bowel disease, ankylosing spondylitis, Behcet’s disease, and juvenile idiopathic arthritis [46]. This evidence concerns the gene TNF and inflammatory bowel disease.